In 2022, I took a risk. I left a great job, great boss, wonderful colleagues, my company of 17 years, and the pharmaceutical industry, where I'd spent my entire career, for an opportunity at a healthcare giant: leading a large research organization and a portfolio of projects developing healthcare-services, quality improvement initiatives, and AI/ML innovations. Unfortunately, just a couple of years in, a series of reorganizations eliminated my position and most of my team. I left feeling disoriented and wondering, where do I go from here?
Reflecting on the past 3 years I realize the gifts this experience has given me: new skills; new ideas that would have never crossed my mind had I stayed put in Pharma; a broad and deep network of talented people in AI/ML, social, network, and actuarial sciences, care delivery, informatics, and more. I was exposed to vastly different company cultures, leadership styles, and workplace norms, which greatly shaped me as a leader. Most of all, my creativity was reignited.
And now it's time for me to go back to what I know and love: innovating to make clinical development work better for everyone. With all I have gained, I am better equipped for the task!
I am an accomplished clinical and healthcare innovation executive, having delivered solutions in partnership with numerous technology and service entrepreneuers and through industry collaborations, including TransCelerate. I've translated, validated, and scaled user research to make trials more doable for participants and sites and spearheaded Johnson & Johnson's program for decentralized clinical trials & direct-to-participant population health research. For my work in innovation, I was named a PharmaVoice 100 honoree and winner of the 2017 Clinical & Research Excellence (CARE) award.
Before this, I managed global clinical trials in pharmaceutical and biotech companies, overseeing trials in patients and healthy volunteers of all phases and multiple therapeutic areas. I consistently achieved trial recruitment on time, within budget, and impeccable quality, contributing to the regulatory approval of several life-changing drugs and vaccines.
I hold a Master of Public Health in Epidemiology from Emory University, a Master of Business Administration in Pharmaceutical Management from Drexel University, and a Bachelor of Science in Molecular Biology and Biochemistry from the University of Idaho.
Novatec G2 is named in honor of my father, Frank Felicione, Ph.D., a brilliant mechanical engineer whose lifelong work has advanced space exploration, nuclear waste management, and the development of clean and sustainable nuclear energy systems. Novatec was the name of my dad's independent consulting business, and G2 stands for "Generation 2," representing me! The atom in my logo reflects my father's nuclear engineering legacy, and the heart nucleus represents G2's focus on advancing human health.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.